Mayne Pharma Group Ltd has released a press release.
Issuance of additional US Patent for NEXTSTELLIS
Filed with ASX ·
Watch Mayne Pharma's latest callMayne Pharma Group (ASX:MYX) Q4 2026 Earnings Call · Replay · Aug 26Read the transcript of Mayne Pharma Group (ASX:MYX) Q4 2026 Earnings Call6ix hasn’t read this filing yet.
Mayne Pharma Group Ltd. on 6ix
Story so far
Earlier from Mayne Pharma
- Mayne Pharma provides update on first quarter 2024 trading and outlook
- Mayne Pharma provides update on 1Q FY24 trading and outlook
- 2023 Full Year Results Investor Presentation
- 2023 Full Year Results Media Release
- Preliminary Final Report
Later from Mayne Pharma
- Mayne Pharma to Present at the 42nd Annual J.P. Morgan Healthcare Conference
- 2024 Half Year Investor Presentation
- 2024 Half Year Media Release
- Mayne Pharma reports 1H FY24 results with A 43% increase in revenue to A$188 million and $8 million underlying EBITDA
- Notification of buy-back - MYX
Follow Mayne Pharma into a list and get an email when it puts out news.
Follow Mayne Pharma